Lexaria Bioscience Corp.
DehydraTECH, a proprietary oral drug delivery technology that enhances bioavailability of active pharmaceutical ingredients
- Sector
- Biotech
- Headquarters
- KELOWNA, A1
- Latest Form D
- $113K, Sep 2026
- Total capital
- $22.7M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $22.7M
- 15 Form D · last Sep 2026
- 1 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 2 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 15th filing$113K
- Private capital raisedForm D · SEC · 14th filing$3.5M
- Private capital raisedForm D · SEC · 13th filing$4M
- Private capital raisedForm D · SEC · 12th filing$5M
- Private capital raisedForm D · SEC · 11th filing$365K
- Private capital raisedForm D · SEC · 10th filing$3.6M
- Private capital raisedForm D · SEC · 9th filing$1.6M
- Private capital raisedForm D · SEC · 8th filing$1.2M
- Private capital raisedForm D · SEC · 7th filing$85K
- Private capital raisedForm D · SEC · 6th filing$100K
- Private capital raisedForm D · SEC · 5th filing$2M
- Private capital raisedForm D · SEC · 4th filing$493K
- Private capital raisedForm D · SEC · 3rd filing$180K
- Private capital raisedForm D · SEC · 2nd filing$310K
- Private capital raisedForm D · SEC · 1st filing$109K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Albert Edward ReeseDirectorNamed in SEC Form D filings
- Allan W. SpissingerExecutive OfficerNamed in SEC Form D filings
- Bal Edward BhullarDirectorNamed in SEC Form D filings
- BRIAN QUIGLEYDirectorNamed in SEC Form D filings
- CATHERINE TURKELDirectorNamed in SEC Form D filings
- CHRIS BUNKAExecutive Officer, DirectorNamed in SEC Form D filings
Show all 15 people
- Christopher BunkaExecutive Officer, DirectorNamed in SEC Form D filings
- GREGORY DOWNEYExecutive OfficerNamed in SEC Form D filings
- JOHN DOCHERTYExecutive Officer, DirectorNamed in SEC Form D filings
- Michael ShankmanExecutive OfficerNamed in SEC Form D filings
- Nelson CabatuanExecutive OfficerNamed in SEC Form D filings
- NICHOLAS BAXTERDirectorNamed in SEC Form D filings
- Richard ChristopherExecutive Officer, DirectorNamed in SEC Form D filings
- TED MCKECHNIEDirectorNamed in SEC Form D filings
- William Edward McKechnieDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 2- PendingEnhancement of Delivery of Lipophilic Active Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System DisordersUSPTOApplication 62748520
- PendingLipophilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use ThereofUSPTOApplication 62730645
Related companies, and why
- Faraday BiosciencesSimilar federal contract value in Biotech · null in contracts
- Capra Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Skylark BioSimilar federal contract value in Biotech · null in contracts
- SciSparc Ltd.Similar federal contract value in Biotech · null in contracts
- Renovion, Inc.Similar federal contract value in Biotech · null in contracts
- Mestag TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .